For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, CRISPR Therapeutics AG’s stock clocked out at $46.91, down -0.21% from its previous closing price of $47.01. In other words, the price has decreased by -$0.21 from its previous closing price. On the day, 0.98 million shares were traded. CRSP stock price reached its highest trading level at $47.6457 during the session, while it also had its lowest trading level at $46.08.
Ratios:
To gain a deeper understanding of CRSP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.73 and its Current Ratio is at 15.73. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on August 06, 2024, Reiterated its Buy rating but revised its target price to $84 from $88 previously.
On August 02, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $90.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 21 ’24 when Bruno Julianne sold 3,366 shares for $56.09 per share. The transaction valued at 188,799 led to the insider holds 6,745 shares of the business.
Kulkarni Samarth sold 19,582 shares of CRSP for $1,173,232 on Apr 15 ’24. The Chief Executive Officer now owns 208,122 shares after completing the transaction at $59.91 per share. On Mar 15 ’24, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $72.48 each. As a result, the insider received 1,449,628 and left with 208,122 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 4003754240 and an Enterprise Value of 2224922368. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.76 while its Price-to-Book (P/B) ratio in mrq is 2.01. Its current Enterprise Value per Revenue stands at 11.002 whereas that against EBITDA is -6.638.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $37.55. The 50-Day Moving Average of the stock is -16.90%, while the 200-Day Moving Average is calculated to be -24.26%.
Shares Statistics:
It appears that CRSP traded 1.36M shares on average per day over the past three months and 1516830 shares per day over the past ten days. A total of 85.17M shares are outstanding, with a floating share count of 81.36M. Insiders hold about 4.47% of the company’s shares, while institutions hold 61.80% stake in the company. Shares short for CRSP as of 1721001600 were 16115832 with a Short Ratio of 12.07, compared to 1718323200 on 14866549. Therefore, it implies a Short% of Shares Outstanding of 16115832 and a Short% of Float of 21.52.
Earnings Estimates
Currently, 23.0 analysts are dedicated to thoroughly evaluating and rating the performance of CRISPR Therapeutics AG (CRSP) in the stock market.The consensus estimate for the next quarter is -$1.32, with high estimates of -$0.1 and low estimates of -$2.01.
Analysts are recommending an EPS of between -$3.96 and -$7.46 for the fiscal current year, implying an average EPS of -$5.68. EPS for the following year is -$4.93, with 25.0 analysts recommending between $5.05 and -$7.59.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $458.9M, while the lowest revenue estimate was $1.02M, resulting in an average revenue estimate of $55.58M. In the same quarter a year ago, actual revenue was $371.21M
